The biology of mammary transgenes: Five rules

[1]  R. Cardiff,et al.  Comparative pathology of mammary tumorigenesis in transgenic mice. , 1995, Cancer letters.

[2]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[3]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.

[4]  M. Barinaga Knockout mice: round two. , 1994, Science.

[5]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[6]  L. Hennighausen,et al.  Whey acidic protein extrinsically expressed from the mouse mammary tumor virus long terminal repeat results in hyperplasia of the coagulation gland epithelium and impaired mammary development. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[7]  Z. Werb,et al.  Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression [published erratum appears in J Cell Biol 1996 Feb;132(4):following 752] , 1994, The Journal of cell biology.

[8]  B. Hogan,et al.  Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene. , 1994, Cancer research.

[9]  R. Coffey,et al.  Cause of Failure of Lactation in Mouse Mammary Tumor Virus/Human Transforming Growth Factor α Transgenic Mice , 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[10]  W. Muller,et al.  Mammary tumorigenesis and metastasis in transgenic mice. , 1994, Seminars in cancer biology.

[11]  W. Muller,et al.  Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.

[12]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[13]  H. Westphal,et al.  Timing of SV40 oncogene activation by site-specific recombination determines subsequent tumor progression during murine lens development. , 1993, Oncogene.

[14]  B. Hogan,et al.  Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. , 1993, Genes & development.

[15]  W. Muller,et al.  PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas. , 1993, Oncogene.

[16]  R. Cardiff,et al.  Multiple tumor types appear in a transgenic mouse with the ras oncogene. , 1993, The American journal of pathology.

[17]  H. Varmus,et al.  Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Mangues,et al.  Overexpression of the N-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice. , 1992, Oncogene.

[20]  B. Carlsson,et al.  High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  R. Guzman,et al.  Role of endocrine, autocrine, and paracrine interactions in the development of mammary hyperplasia in Wnt-1 transgenic mice. , 1992, Cancer research.

[22]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Cardiff,et al.  Int-2, an autocrine and/or ultra-short-range effector in transgenic mammary tissue transplants. , 1992, Journal of the National Cancer Institute.

[24]  B. Hogan,et al.  Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. , 1992, The American journal of pathology.

[25]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[26]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[27]  D. Gallahan,et al.  Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. , 1992, Genes & development.

[28]  H. Varmus,et al.  Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice , 1992, Molecular and cellular biology.

[29]  S. Cory,et al.  Transgenic models of tumor development. , 1991, Science.

[30]  G. Merlino,et al.  Molecular insights into breast cancer from transgenic mouse models , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[31]  W. Muller Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer , 1991, Cancer and Metastasis Reviews.

[32]  R. Cardiff,et al.  Transgenic oncogene mice. Tumor phenotype predicts genotype. , 1991, The American journal of pathology.

[33]  L. Nielsen,et al.  Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. , 1991, Cancer research.

[34]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[35]  P. Leder,et al.  Binary system for regulating transgene expression in mice: targeting int-2 gene expression with yeast GAL4/UAS control elements. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Fourney,et al.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.

[37]  L. Orci,et al.  Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene , 1990, Cell.

[38]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice , 1990, Cell.

[39]  D. Roop,et al.  Differential keratin gene expression in developing, differentiating, preneoplastic, and neoplastic mouse mammary epithelium. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[40]  R. Callahan,et al.  Mutations in human breast cancer: an overview. , 1989, Journal of the National Cancer Institute.

[41]  P. Leder,et al.  Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. , 1989, The American journal of pathology.

[42]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[43]  T. Hoang,et al.  Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues , 1989, Molecular and cellular biology.

[44]  B. Groner,et al.  Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. , 1988, Genes & development.

[45]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[46]  B. Groner,et al.  Targeted c‐myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. , 1988, The EMBO journal.

[47]  P. Leder,et al.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.

[48]  B. Groner,et al.  Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[49]  N. Glaichenhaus [Cooperation between oncogenes: the function of immortalizing oncogenes]. , 1986, Pathologie-biologie.

[50]  Alan E. Smith,et al.  Polyoma virus transforming protein associates with the product of the c-src cellular gene , 1983, Nature.

[51]  R. Cardiff,et al.  Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. , 1994, Genes & development.

[52]  R. Cardiff,et al.  Transgenic mouse models of mammary tumorigenesis. , 1993, Cancer surveys.

[53]  R. Cardiff,et al.  Mammary Morphogenesis and Oncogenes , 1992 .

[54]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. , 1990, Cell.

[55]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[56]  R. Cardiff Protoneoplasia: the molecular biology of murine mammary hyperplasia. , 1984, Advances in cancer research.

[57]  F. X. Demers,et al.  [Mammary tumors]. , 1957, Laval medical.